Iterum Therapeutics plc (ITRM) - Dilution Analysis

10-Q filing | 45.8M shares outstanding

10-Q filing | 44.7M shares outstanding

10-Q filing | 40.0M shares outstanding

10-K filing | 34.6M shares outstanding

S-3 filing: Iterum Therapeutics PLC may offer and sell, from time to time, securities up to an aggregate offering price of $150,000,000.

10-Q filing | 27.5M shares outstanding

10-Q filing | 22.7M shares outstanding

POS AM filing: This POS AM filing deregisters unsold securities from a previous offering, specifically 2,381,835 units, consisting of ordinary shares, 1-year warrants, 5-year warrants, and warrant shares that were registered but unsold.

S-1/A filing: Iterum Therapeutics PLC is conducting a rights offering to holders of its ordinary shares and eligible warrant holders to purchase Units, with each unit consisting of one ordinary share, a 1-year warrant to purchase 0.50 ordinary shares at an exercise price of $1.21, and a 5-year warrant to purchase one ordinary share at an exercise price of $1.21, for aggregate gross proceeds of approximately $10.3 million.

S-1/A filing: Iterum Therapeutics plc is distributing non-transferable subscription rights to purchase Units, with each unit consisting of one ordinary share, a 1-year warrant to purchase 0.5 ordinary shares, and a 5-year warrant to purchase one ordinary share, to holders of ordinary shares and eligible warrant holders.

8-K filing: Iterum Therapeutics plc announced a proposed rights offering to distribute subscription rights to purchase an aggregate of 8,503,800 units at a subscription price of $1.21 per unit. ($0.0M proceeds)

S-1 filing: Iterum Therapeutics PLC is offering subscription rights to purchase Units, consisting of ordinary shares and warrants, to holders of its ordinary shares and eligible warrant holders, with the offering managed by Maxim Group LLC as dealer-manager.

10-Q filing | 15.4M shares outstanding

10-K filing | 16.4M shares outstanding

10-Q filing | 13.0M shares outstanding

10-Q filing | 12.9M shares outstanding

10-Q filing | 12.7M shares outstanding

10-K filing | 12.2M shares outstanding

10-Q filing | 12.2M shares outstanding

S-3 filing: The company is offering ordinary shares through an at-the-market offering, with H.C. Wainwright & Co., LLC acting as the sales agent, for an aggregate offering price of up to $16,000,000, not to exceed 4,478,180 ordinary shares.

8-K filing: Stock split 1-for-15 | Outstanding: 183,364,740 → 12,224,316

10-Q filing | 183.4M shares outstanding

10-Q filing | 183.4M shares outstanding

10-K filing | 182.8M shares outstanding

10-Q filing | 182.7M shares outstanding

10-Q filing | 180.0M shares outstanding

10-Q filing | 179.1M shares outstanding

10-K filing | 176.5M shares outstanding

10-Q filing | 43.0M shares outstanding

S-1/A filing: The company is offering ordinary shares and warrants, as well as pre-funded warrants and warrants, with the net proceeds intended to support the planned NDA submission for oral sulopenem and for working capital and general corporate purposes.

S-1/A filing: The company is offering 13,407,821 ordinary shares and warrants to purchase ordinary shares, as well as pre-funded warrants to purchase ordinary shares and warrants, with the net proceeds to be used for NDA submission, clinical development, working capital, and general corporate purposes.

S-1 filing: The company is filing an S-1 to offer ordinary shares, warrants, and pre-funded warrants, with the intention to use the net proceeds to support the NDA submission for oral sulopenem for the treatment of uUTI, continued clinical development of sulopenem, and for working capital and general corporate purposes.

S-1/A filing: This S-1/A filing relates to an offering of 6.500% Exchangeable Senior Subordinated Notes due 2025, Limited Recourse Royalty-Linked Subordinated Notes, and ordinary shares offered by selling shareholders.

S-1 filing: This S-1 filing includes the offering of 6.500% Exchangeable Senior Subordinated Notes due 2025, Limited Recourse Royalty-Linked Subordinated Notes, and Ordinary Shares by selling shareholders.

S-1 filing: S-1 filing for ordinary shares offered by selling shareholders.

8-K filing: Iterum Therapeutics plc announced that it had commenced its previously announced rights offering for up to 8,400 units at $1,000 per unit, each unit consisting of Exchangeable Senior Subordinated Notes and Limited Recourse Royalty-Linked Subordinated Notes. ($8.4M proceeds)

10-Q filing | 21.2M shares outstanding

S-1/A filing: Iterum Therapeutics is distributing non-transferable subscription rights to purchase units consisting of Exchangeable Senior Subordinated Notes and Limited Recourse Royalty-Linked Notes, with the rights expiring on August 31, 2020, unless extended.

8-K filing: On June 10, 2020, Iterum Therapeutics plc shareholders approved an amendment to the Company's 2018 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 2,250,000.

10-Q filing | 14.9M shares outstanding

S-1/A filing: Iterum Therapeutics is conducting a rights offering to distribute non-transferable subscription rights to purchase units consisting of Exchangeable Senior Subordinated Notes and Limited Recourse Royalty-Linked Notes.

S-1/A filing: Iterum Therapeutics is conducting a rights offering to distribute non-transferable subscription rights to purchase units consisting of Exchangeable Senior Subordinated Notes and Royalty-Linked Notes.

S-1 filing: Iterum Therapeutics is conducting a rights offering to distribute non-transferable subscription rights to purchase units consisting of Exchangeable Senior Subordinated Notes and Royalty-Linked Notes.

10-K filing | 14.9M shares outstanding